Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial

Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial

Background: Molecular profiling (MP) represents an opportunity to match patients to a targeted therapy and when tumor tissue is unavailable, circulating tumor deoxyribonucleic acid (ctDNA) can be harnessed as a non-invasive analyte for this purpose. We evaluated the success of a targeted therapy sel...

Full description

Bibliographic Details
Main Authors: Jakob M. Riedl, Samantha O. Hasenleithner, Gudrun Pregartner, Lukas Scheipner, Florian Posch, Karin Groller, Karl Kashofer, Stephan W. Jahn, Thomas Bauernhofer, Martin Pichler, Herbert Stöger, Andrea Berghold, Gerald Hoefler, Michael R. Speicher, Ellen Heitzer, Armin Gerger
Format: Article
Language:English
Published: SAGE Publishing 2021-02-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920987658

Internet

https://doi.org/10.1177/1758835920987658

Similar Items